



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/57, 31/565	A1	(11) International Publication Number: WO 98/04268 (43) International Publication Date: 5 February 1998 (05.02.98)
(21) International Application Number: PCT/US97/12786 (22) International Filing Date: 23 July 1997 (23.07.97) (30) Priority Data: 08/686,786 26 July 1996 (26.07.96) US (71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US). (72) Inventor: GAST, Michael, Jay; 230 Country Lane, Phoenixville, PA 19460 (US). (74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ORAL CONTRACEPTIVE (57) Abstract This invention provides a method of contraception which comprises administering to a female of child bearing age for 23-25 consecutive days, a first phase combination of a progestin at a daily dosage of 40-500 μ g trimegestone, 250 μ g - 4mg dienogest, or 250 μ g - 4mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen combination is administered in each of the 3-8 days, a second phase combination of a progestin at a daily dosage of 40-500 μ g trimegestone, 250 μ g - 4 mg dienogest, or 250 μ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol, for 4-15 days, beginning on the day immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days, and a third phase combination of a progestin at a daily dosage of 40-500 μ g trimegestone, 250 μ g - 4 mg dienogest, or 250 μ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the second phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days provided that the daily dosage of the combination administered in the first phase is not the same as the daily dosage of the combination administered in the second phase and that the daily dosage of the combination administered in the second phase is not the same as the daily dosage of the combination administered in the third phase.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

ORAL CONTRACEPTIVE**BACKGROUND OF THE INVENTION**

5 The vast majority of oral contraceptives consist of a combination of a progestin and estrogen that are administered concurrently for 21 days followed either by a 7 day pill free interval or by the administration of a placebo for 7 days in each 28 day cycle. The most important aspects of a successful oral contraceptive product are effective contraception, good cycle control (absence of spotting and breakthrough bleeding and
10 occurrence of withdrawal bleeding), and minimal side effects. Combination oral contraceptives have traditionally acted by suppression of gonadotropins. In addition, it appears that the progestin component is primarily responsible for contraceptive efficacy through inhibition of ovulation, and other peripheral effects which include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the
15 endometrium (which reduce the likelihood of implantation). The estrogenic component intensifies the anovulatory effect of the progestin, and is also important for maintaining cycle control.

 Since the introduction of oral contraceptives (OCs) over a quarter-century ago, research has been directed toward developing preparations that minimize the potential
20 for side effects while maintaining efficacy and normal menstrual patterns. The first-generation OCs contained more progestin and estrogen than was necessary to prevent conception. Adverse hemostatic and metabolic changes, clinical problems, and side effects were associated with these high-dose preparations. In 1978, the World Health Organization (WHO) recommended that the focus of OC research should be the
25 development of products containing the lowest possible dose levels of estrogen and progestin.

 The first reductions in steroid content in a combination pill were focused on estrogen because it, rather than progestin, was thought to be related to the most serious side effects. Reduction in progestin content followed, as evidence mounted that
30 lowering progestin intake might lower the risk of cardiovascular complications such as stroke and ischemic heart disease. [Kay CR, Am J Obstet Gynecol 142:762 (1982)]. However, this evidence was not as clear as that implicating estrogen in thromboembolic disorders. [Inman WHW, Br Med J 2:203 (1970); Stolley PD, Am J Epidemiol 102:197 (1975)]. The need for a balance between estrogens and progestins to minimize
35 adverse effects on carbohydrate metabolism and on lipid and lipoprotein levels was also recognized. [Bradley DD, N Engl J Med 299:17 (1978); Wynn V, Lancet 1:1045

- 2 -

(1979)]. Researchers then found that the synergistic action between progestin and estrogen in a balanced ratio successfully inhibited ovulation at low levels of both components.

5 Research into low-dose progestins was advanced significantly by the development of norgestrel (Ng) and levonorgestrel (LNg). Levonorgestrel is the biologically active moiety of racemic norgestrel. It is strongly progestational, has no inherent estrogenic activity, is antiestrogenic, and possesses good biologic activity. The contraceptive effects of levonorgestrel are manifested throughout the hypothalamic-pituitary-gonadal-target organ axis.

10 Ethinyl estradiol (EE) is the estrogen most frequently used in combination OCs. In attempts to fulfill the WHO objective, the dosage of EE in marketed OC formulations has been steadily reduced from that found in earlier OCs. Thromboembolic mortality decreased when the amount of synthetic estrogen in OC formulations was reduced from 100 µg to 50 µg. Subsequently, a significant reduction in fatal myocardial infarctions
15 was reported for women using OCs with 30 µg of EE rather than 50 µg of EE. [Meade TW, Br Med J 280:1157 (1980)].

In keeping with the goal of reducing the total steroidal dosage, while maintaining contraceptive efficacy, good cycle control, and minimizing side effects, numerous regimens have been developed in which the progestin/estrogen combination
20 is administered either as a fixed dosage combination (monophasic) or as biphasic or triphasic regimens in which the dosage of the combination is varied either once or twice throughout the menstrual cycle. In these regimens, the progestin/estrogen combination is typically administered for 21 days followed by either a 7-day pill free period or the administration of a non-contraceptive placebo (or iron supplement) for 7 days. In these
25 regimens, 3-ketodesogestrel (3-KDSG), desogestrel (DSG), levonorgestrel (LNg), gestodene (GTD), norgestrel (NG), and norethindrone (NE) are typically used as the progestin while ethinyl estradiol (EE); 17β-estradiol, and mestranol are typically the estrogenic components. Other progestins less frequently used include drospirenone (DRSP) and dienogest (DGST).

30 An oral contraceptive product containing a combination of 3 mg DGST and 30 µg EE for 21-day administration per cycle is marketed in Germany.

Several examples of attempts at reducing the total steroidal dosage are provided below.

35 Spona (PCT Publication WO 95/17194) discloses contraceptive regimens which consist of the administration of a combination of a progestin (50 - 75 µg GTD, 75 - 125 µg LNg, 60 - 150 µg DSG, 60 - 150 µg 3-KDSG, 100 - 300 µg DRSP, 100 - 200 µg

- 3 -

cypoterone acetate, 200 - 300 μ g norgestimate, or >350 - 750 μ g norethisterone) and an estrogen (15 - 20 μ g EE or 2 - 6 mg 17 β -estradiol) for 23-24 days per cycle.

Oettel (EP 628,312 A1) discloses combination contraceptive combinations containing the combination of three components: a biogenic estrogen (estradiol, estrone, or estriol), a synthetic estrogen (EE or mestranol), and a progestin (LNg, desogestrel, progesterone, norethisterone acetate, DGST, chlormadinone acetate, gestodene, or cypoterone acetate). In one embodiment, the combination is administered for 21 days followed by the administration of placebo (or pill free) or an estrogen on days 22-28 of the cycle.

10 Bergink (U.S. Patent 5,262,408) discloses a 24 day triphasic combination regimen in which the first 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 100 μ g DSG and an estrogen at a daily dosage equivalent to 25 μ g EE, the second 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 125 μ g DSG and an estrogen at a daily dosage equivalent to 20 μ g EE, and the third 7-9 day phase consists of the administration of a progestin at a daily dosage equivalent to 50 μ g DSG and an estrogen at a daily dosage equivalent to 20 μ g EE. It is preferred that the three phases be 8 days each. Following the 24 day contraceptive steroid administration, a placebo may be administered for 4 days, the 4 day interval may be pill free, or a progestin at a dosage equivalent to 25-35 μ g DSG may be administered.

20 Lachnit-Fixson (U.S. Patent 3,957,982) discloses triphasic 21-day progestin/estrogen regimens in which a combination of 40-90 μ g LNg and 20-50 μ g EE is administered for 4-6 days in the first phase, 50-125 μ g LNg and 30-50 μ g EE is administered for 4-6 days in the second phase, and 100-250 μ g LNg and 25-50 μ g EE is administered for 9-11 days in the third phase. It is preferred that the first, second, and third phases are 6, 5, and 10 days, respectively.

30 Bennick (U.S. Patent 5,418,228) discloses triphasic regimens which consist of the administration of a combination progestin/estrogen in a 6-8 day phase, a second 6-8 day phase, and a third 6-8 day phase, with it being preferred that the three contraceptive steroid phases be 7 days each. Bennick discloses that the first contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 150 μ g DSG and an estrogen at a daily dosage equivalent to 20 - 25 μ g EE; the second contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 125 μ g DSG and an estrogen at a daily dosage equivalent to 20 μ g EE; and the third contraceptive steroid phase consists of a progestin at a daily dosage equivalent to 75 - 100 μ g DSG

- 4 -

and an estrogen at a daily dosage equivalent to 20 µg EE. Placebo is administered for 7 days following the 21-day contraceptive steroid period. Bennick discloses that the progestin may be 3-KDSG, DSG, LNg, or GTD.

Boissonneault (U.S. Patent 4,962,098) discloses triphasic progestin/estrogen combinations in which the amount of the estrogenic component is increased stepwise over the three phases. Contraceptive steroid combinations are taken for 4-7 days during the first phase (5 days being preferred); for 5-8 days during the second phase (7 days preferred); and for 7-12 days during the third phase (9 days being preferred). Following the administration of 21-days of the contraceptive steroid combination, placebo is taken for 7 days. For all three phases, 0.5-1.5 mg of norethindrone acetate is used in the progestin, with 1 mg being preferred. 10-30 µg EE is used in the first phase, 20-40 µg in the second, and 30-50 µg in the third phase.

Pasquale (U.S. Patent 4,921,843) discloses combination progestin/estrogen contraceptive regimens which contain 0.5 to 1 mg of progestin and an estrogen having a dose equivalent to 10-40 µg of EE. NE, LNg, D-17β-acetoxy-13β-ethyl-17α-ethinylgon-4-en-3-one oxime, and 19-nor-17-hydroxy progesterone ester are disclosed as progestins, with NE being preferred. Specifically disclosed regimens include a uniphasic regimen (2 days of placebo, 5 days of 20 µg EE, and 21 days of a combination of 500 µg NE and 35 µg EE); a uniphasic regimen (2 days of placebo, 5 days of 40 µg EE, and 21 days of a combination of 500 µg NE and 35 µg EE); and a triphasic regimen (2 days of placebo; 5 days of 20-40 µg EE; 7 days of a combination of 500 µg NE and 35 µg EE; 7 days of a combination of 750 µg NE and 35 µg EE; and 7 days of a combination of 1 mg NE and 35 µg EE).

Pasquale (U.S. Patent 4,628,051) discloses triphasic progestin/estrogen combination regimens in which contraceptive steroid is administered for 21 days. Contraceptive steroid combinations are taken for 5-8 days during the first phase (7 days being preferred); for 7-11 days during the second phase (7 days preferred); and for 3-7 days during the third phase (7 days being preferred). In all three phases, an estrogen at a daily dosage equivalent to 20-50 µg EE is administered in combination with a progestin having a daily dosage equivalent to 65-750 µg NE in the first phase, 0.25-1.0 mg NE in the second phase, and 0.35-2.0 mg NE in the third phase. A specific triphasic regimen discloses the administration of 35 µg EE in each of the three 7-day phases in combination with 0.5 mg, 0.75 mg, and 1.0 mg in the first, second, and third phases, respectively. A second specific triphasic regimen discloses the administration of 35 µg EE in each of the three 7-day phases in combination with

- 5 -

50 µg, 75 µg, and 100 µg in the first, second, and third phases, respectively. A third specific triphasic regimen discloses the administration of 35 µg EE in each of the three 7-day phases in combination with 25 µg, 35 µg, and 50 µg in the first, second, and third phases, respectively.

5 Lachnit-Fixson (U.S. Patent 4,621,079) discloses triphasic 21-day progestin/estrogen combination regimens in which a combination of 40-70 µg GTD and 20-35 µg EE is administered for 4-6 days in the first phase; 50-100 µg GTD and 30-50 µg EE is administered for 4-6 days in the second phase; and 80-120 µg GTD and 20-50 µg EE is administered for 9-11 days in the third phase. Placebo is
10 administered for 7 days following the 21-day contraceptive steroid regimen.

Pasquale (U.S. Patent 4,530,839) discloses triphasic 21-day progestin/estrogen combination regimens in which a dose of 20-50 µg EE is administered in all three phases in combination with a contraceptively effective daily dose of progestin in the first phase, 1.5-2 times that dose of progestin in the second phase, and 2-2.5 times the
15 first phase dose of progestin in the third phase. Each of the three phases is 7 days long. A specific regimen discloses 20-50 µg EE in combination with 500 µg LNg, 750 µg LNg, and 1 mg LNg during each of the three 7-day phases, respectively.

Edgren (U.S. Patent 4,390,531) discloses triphasic 21-day progestin/estrogen combination regimens in which a dose of 20-40 µg EE (or another estrogen in an
20 equivalent dosage) is administered in all three phases in combination with 0.3-0.8 mg NE (or another progestin in an equivalent dosage) for 5-8 days in the first phase, twice the dose of NE for 7-11 days in the second phase, and the dose of NE being the same as in the first phase for 3-7 days in the third phase. It is preferred that each of the three phases is 7 days. Placebo is administered for 6-8 days following administration of the
25 contraceptive steroid combination. A specific regimen discloses a first phase of 7 days of 0.5 mg NE in combination with 35 µg EE, a second 7 day phase of 1.0 mg NE in combination with 35 µg EE, and a third 7 day phase of 0.5 mg NE in combination with 35 µg EE.

Upton (EP Patent Specification 253,607 B1) teaches the use of low dose
30 progestin/estrogen combinations for combined hormone replacement therapy and contraception in climacteric women. Climacteric women are defined in Upton as premenopausal women around 40 years of age whose hormone levels are waning. The climacteric woman still ovulates (albeit may have irregular ovulation), but she still experiences many of the symptoms of the hypoestrogenic menopausal woman, such as
35 insomnia, hot flushes, and irritability. Upton teaches the administration of a 23-26 day

- 6 -

monophasic regimen of progestin/estrogen followed by a pill free or placebo interval of 2-5 days; with 24 days of progestin/estrogen administration followed by a 4-day pill free or placebo administration being preferred. Upton teaches the use of a progestin selected from 25 - 100 µg LNg, 10 - 70 µg GTD, 25 - 100 µg DSG, 25 - 100 µg 3-KDSG, and 85 - 350 µg NE used in combination with an estrogen selected from 500 - 2000 µg 17β-estradiol, 8 - 30 µg EE, and 15 - 60 µg mestranol. Based on relative potencies, Upton teaches that a dose of 75 µg LNg is equivalent to 35 µg of GTD, 75 µg of 3-KDSG or DSG, and 250 µg NE and that a dose of 1000 µg of 17β-estradiol is equivalent to a dose of 15 µg EE and 30 µg mestranol. Upton also teaches that NG may be substituted for LNg, but at twice the dose.

Sartoretto (Clinica e Terapeutica 3: 399 (1974)) discloses a monophasic contraceptive regimen consisting of the administration of a combination 100 µg LNg and 20 µg EE for 21 days.

Oettel (EP 696,454 A2) discloses a three phase contraceptive regimen in which the first phase consists of the administration for 3-4 days of a composition containing at least one biogenic estrogen; the second phase consists of the administration for 20-22 days of at least one biogenic estrogen and at least one progestin (progesterone, DGST, desogestrel, 3-KDSG, GTD, LNg, norgestimate, notethisterone, norethisterone acetate, dehydrogestrone, chloromadinone acetate, cyproterone acetate, medroxyprogesterone acetate, or megestrol acetate); and the third phase consists of the administration for 3-4 days of a composition containing at least biogenic one estrogen.

Lachnit (PCT Publication WO 95/26730) discloses bridged regimens consisting of the administration of a combination of a progestin/estrogen combination (50 - 125 µg LNg and 10 - 40 µg EE) for the first 23-24 days of the menstrual cycle followed by the administration of an estrogen (2 - 40 µg EE) for 4-10 days for a total administration of at least 28 days per cycle. The use of 100 - 300 µg drospirenone and 10 - 40 µg EE as the 23-24 day progestin/estrogen combination is disclosed. Lachnit also discloses a triphasic plus bridging regimen (4-9 days, 4-9 days, 9-13 days, and 28 days for the three phases and estrogen phase, respectively) in which a combination of 50 µg LNg and 20 µg EE are administered in the first phase, a combination of 75 µg LNg and 25 µg EE are administered in the second phase, a combination of 100 µg LNg and 20 µg EE are administered in the third phase, and 10 µg EE is administered in the estrogen phase. Other progestins disclosed include GTD, DSG, 3-KDSG, DRSP, cyproterone acetate, norgestimate, and norethisterone.

Moore (DE 4313926 A1) discloses bridged triphasic regimens consisting of the administration of a combination of 10 - 50 µg LNg and 5 - 20 µg EE from days 1-7 of

- 7 -

the menstrual cycle; of 50 - 75 μ g LNg and 5 - 20 μ g EE from days 8-14 of the menstrual cycle; of 75 - 125 μ g LNg and 5 - 20 μ g EE from days 15-21 of the menstrual cycle; and 5 - 20 μ g EE from days 22-28 of the menstrual cycle.

Erlich (German Patent DE 4,104,385 C1 and U.S. Patent 5,280,023) discloses sequential contraceptive regimens consisting of the administration of an estrogen which effects a disturbance of follicle stimulation, followed by the administration of a combination of a progestin/estrogen in a dose at least adequate to inhibit ovulation. The regimen is administered for a total of 28 days per cycle. It is preferred that the estrogen is administered for 5-14 days per cycle and the progestin/estrogen combination is administered for 23-14 days per cycle, so that the total administration is for 28 days per cycle. Specific regimens include (a) 4 mg estradiol for 7 days followed by 21 days of the combination of 1 mg norethisterone acetate and 4 mg estradiol; (b) 2 mg estradiol valerate for 7 days followed by 21 days of the combination of 2 mg chlormadinone acetate and 4 mg estradiol valerate; and (c) 20 μ g EE followed by 18 days of the combination of 150 μ g LNg and 20 μ g EE. Regimen (c) in Erlich provides a total steroidal load of 2.7 mg of LNg and 560 μ g EE per 28 day cycle.

Lachnit-Fixson (U.S. Patent 3,969,502) discloses biphasic progestin/estrogen combination regimens in which a combination of 50-125 μ g LNg and 25-35 μ g EE are administered for 10-12 days in the first phase and 100-350 μ g LNg and 30-50 μ g EE are administered for 10-12 days in the second phase. Placebo is administered for 5-7 days following the administration of the contraceptive steroid regimen.

DESCRIPTION OF THE INVENTION

This invention provides a triphasic combination progestin/estrogen oral contraceptive regimen for females of child-bearing age that provides effective contraception, good cycle control, and minimal side effects while greatly reducing the total contraceptive steroid administered (particularly the estrogenic component) per 28-day cycle. To achieve the substantial reduction in the total contraceptive steroid administered per cycle, the low dose progestin/estrogen combination is administered for 23-25-days per cycle according to a triphasic regimen that is described below. Administration of the contraceptive progestin/estrogen combination is begun on the first day of menses (day 1), and continued for 23-25 consecutive days. Following the 23-25-day administration period, a non-contraceptive placebo (devoid of progestins and estrogens) can be provided for 3-5 days, so that the total administration period per cycle

- 8 -

is 28 days per cycle to aid in compliance with the desired contraceptive regimen. Alternatively, the 3-5-day interval can be pill free.

More particularly, this invention provides a method of contraception which comprises administering to a female of child bearing age a first phase of a combination
5 of a progestin at a daily dosage of 40-500 μ g trimegestone, 250 μ g - 4 mg dienogest, or 250 μ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle. The same daily dosage of the progestin and estrogen is administered for each of the 3-8 days. A second phase of a combination of a progestin at a daily dosage of 40-
10 500 μ g trimegestone, 250 μ g - 4 mg dienogest, or 250 μ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol is administered for 4-15 days beginning on the day immediately following the last day of administration of the first phase. The same daily dosage of the progestin and estrogen is administered for each of the 4-15 days. A third phase of a combination of a
15 progestin at a daily dosage of 40-500 μ g trimegestone, 250 μ g - 4 mg dienogest, or 250 μ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol is administered for 4-15 days beginning on the day immediately following the last day of administration of the second phase. The same
20 daily dosage of the progestin and estrogen is administered for each of the 4-15 days. The total administration for all three phases is 23-25 days. The daily dosage of the progestin/estrogen combination administered in any phase is distinct from the dosage of the progestin/estrogen combination administered in either of the other two phases.

Following the 23-25-day period, a non-contraceptive placebo, which may
25 contain an iron supplement, such as 75 mg of ferrous fumarate, may be administered for 3-5 days (through day 28 of the menstrual cycle) or the 3-5 days following administration of the contraceptive combination may be pill free.

It is preferred that total administration of the progestin/estrogen combination be 24 days. Preferred phase lengths are shown in the following table, with Phase
30 Regimens A and B being most preferred for the triphasic rising regimens that are described below, and Phase Regimens E and F are most preferred for the triphasic midpeak regimens that are described below.

- 9 -

	<u>Phase Regimen</u>	<u>Phase 1 (days)</u>	<u>Phase 2 (days)</u>	<u>Phase 3 (days)</u>
5	A	7	7	10
	B	5	5	14
	C	5	8	11
	D	6	6	12
	E	7	10	7
	F	6	12	6
10	G	6	8	10
	H	4	8	12
	I	5	14	5
	J	6	10	8

15

Preferred estrogens include, but are not limited to ethinyl estradiol; 17 β -estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol; with ethinyl estradiol being more preferred. Preferred salts of estrone include, but are not limited to the sodium and piperate salt. When conjugated estrogens, USP are used as the estrogen, it is preferred that the daily dosage is 0.3-5 mg, with a daily dose of 1.25 mg conjugated estrogens, USP being equivalent to a daily dose of 15 μ g ethinyl estradiol.

In one specific preferred embodiment of this invention termed a "triphasic rising regimen," the dosage of progestin is higher in the second phase than in the first phase and is higher in the third phase than in the second phase. With these regimens, the third phase will generally have the longest duration. In general, the estrogen dosage in the second phase is greater than the first phase, and the estrogen dosage in third phase is greater than the second phase; can rise from the first phase to the second phase, and then remain the same for the third phase; or can remain the same for all three phases.

The following daily dosages of a combination of trimegestone and ethinyl estradiol are preferred for contraception when administered according to a triphasic rising regimen for 23-25 consecutive days beginning on the first day of menses, with 24 days being preferred. The preferred phase lengths are provided above. Of the regimens provided below, Regimen B is more preferred. In the table below, trimegestone is abbreviated as TMG and ethinyl estradiol is abbreviated as EE.

- 10 -

PREFERRED DAILY DOSAGES (in μg)

	<u>Regimen</u>	<u>Phase 1</u>		<u>Phase 2</u>		<u>Phase 3</u>	
		<u>TMG</u>	<u>EE</u>	<u>TMG</u>	<u>EE</u>	<u>TMG</u>	<u>EE</u>
5	A	75	10	125	15	250	20
	B	50	10	75	15	125	20
	C	40	10	50	15	75	20
	D	50	10	75	15	125	15
	E	50	10	75	10	125	15

10

The following daily dosages of a combination of dienogest and ethinyl estradiol are preferred for contraception when administered according to a triphasic rising regimen for 23-25 consecutive days beginning on the first day of menses, with 24 days being preferred. The preferred phase lengths are provided above. Of the regimens provided below, Regimen B is more preferred. In the table below, dienogest is abbreviated as DGST and ethinyl estradiol is abbreviated as EE.

20

PREFERRED DAILY DOSAGES

	<u>Regimen</u>	<u>Phase 1</u>		<u>Phase 2</u>		<u>Phase 3</u>	
		<u>DGST</u>	<u>EE</u>	<u>DGST</u>	<u>EE</u>	<u>DGST</u>	<u>EE</u>
	A	750 μg	10 μg	1 mg	15 μg	2 mg	20 μg
	B	500 μg	10 μg	750 μg	15 μg	1 mg	20 μg
25	C	750 μg	10 μg	1 mg	15 μg	2 mg	15 μg
	D	500 μg	10 μg	750 μg	15 μg	1 mg	15 μg

The following daily dosages of a combination of drospirenone and ethinyl estradiol are preferred for contraception when administered according to a triphasic rising regimen for 23-25 consecutive days beginning on the first day of menses, with 24 days being preferred. The preferred phase lengths are provided above. Of the regimens provided below, Regimen B is more preferred. In the table below, drospirenone is abbreviated as DRSP and ethinyl estradiol is abbreviated as EE.

35

- 11 -

PREFERRED DAILY DOSAGES

	<u>Regimen</u>	<u>Phase 1</u>		<u>Phase 2</u>		<u>Phase 3</u>	
		<u>DRSP</u>	<u>EE</u>	<u>DRSP</u>	<u>EE</u>	<u>DRSP</u>	<u>EE</u>
5	A	2 mg	10 μ g	3 mg	15 μ g	4 mg	20 μ g
	B	1 mg	10 μ g	2 mg	15 μ g	3 mg	20 μ g
	C	500 μ g	10 μ g	1 mg	15 μ g	2 mg	20 μ g
	D	2 mg	10 μ g	3 mg	15 μ g	4 mg	15 μ g
	E	1 mg	10 μ g	2 mg	15 μ g	3 mg	15 μ g
	F	500 μ g	10 μ g	1 mg	15 μ g	2 mg	15 μ g

10

In another specific preferred embodiment of this invention termed a "triphasic mid-peak regimen," the dosage of progestin is typically highest in the second phase. The dosage of progestin in the third phase is generally, though not necessarily, higher than in the first phase. With these regimens, the second phase will generally have the longest duration. In general, the estrogen can rise so that the dosage in the second phase is greater than the first phase, and the dosage in third phase is greater than the second phase; can rise from the first phase to the second phase, and then remain the same for the third phase; can remain the same for all three phases; or can be "mid-peak" so that the dose in the second phase is highest, with the dose in the third phase generally being higher than the first phase.

The following daily dosages of a combination of trimegestone and ethinyl estradiol are preferred for contraception when administered according to a triphasic mid-peak regimen for 23-25 consecutive days beginning on the first day of menses, with 24 days being preferred. The preferred phase lengths are provided above. Of the regimens provided below, Regimen B is more preferred. In the table below, trimegestone is abbreviated as TMG and ethinyl estradiol is abbreviated as EE.

PREFERRED DAILY DOSAGES (in μ g)							
	<u>Regimen</u>	<u>Phase 1</u>		<u>Phase 2</u>		<u>Phase 3</u>	
		<u>TMG</u>	<u>EE</u>	<u>TMG</u>	<u>EE</u>	<u>TMG</u>	<u>EE</u>
30	A	75	10	250	20	125	15
	B	50	10	125	20	75	15
	C	40	10	75	20	50	15
35	D	50	10	125	15	75	15
	E	50	10	125	15	75	10

- 12 -

The following daily dosages of a combination of dienogest and ethinyl estradiol are preferred for contraception when administered according to a triphasic mid-peak regimen for 23-25 consecutive days beginning on the first day of menses, with 24 days being preferred. The preferred phase lengths are provided above. Of the regimens provided below, Regimen B is more preferred. In the table below, dienogest is abbreviated as DGST and ethinyl estradiol is abbreviated as EE.

PREFERRED DAILY DOSAGES

10	<u>Regimen</u>	<u>Phase 1</u>		<u>Phase 2</u>		<u>Phase 3</u>	
		<u>DGST</u>	<u>EE</u>	<u>DGST</u>	<u>EE</u>	<u>DGST</u>	<u>EE</u>
	A	750 µg	10 µg	2 mg	20 µg	1 mg	15 µg
	B	500 µg	10 µg	1 mg	20 µg	750 µg	15 µg
	C	750 µg	10 µg	2 mg	15 µg	1 mg	15 µg
	D	500 µg	10 µg	1 mg	15 µg	750 µg	15 µg

15

The following daily dosages of a combination of drospirenone and ethinyl estradiol are preferred for contraception when administered according to a triphasic mid-peak regimen for 23-25 consecutive days beginning on the first day of menses, with 24 days being preferred. The preferred phase lengths are provided above. Of the regimens provided below, Regimen C is more preferred. In the table below, drospirenone is abbreviated as DRSP and ethinyl estradiol is abbreviated as EE.

PREFERRED DAILY DOSAGES

25	<u>Regimen</u>	<u>Phase 1</u>		<u>Phase 2</u>		<u>Phase 3</u>	
		<u>DRSP</u>	<u>EE</u>	<u>DRSP</u>	<u>EE</u>	<u>DRSP</u>	<u>EE</u>
	A	2 mg	10 µg	4 mg	20 µg	3 mg	15 µg
	B	1 mg	10 µg	3 mg	20 µg	2 mg	15 µg
	C	500 µg	10 µg	2 mg	20 µg	1 mg	15 µg
	D	2 mg	10 µg	4 mg	15 µg	3 mg	15 µg
30	E	1 mg	10 µg	3 mg	15 µg	2 mg	15 µg
	F	500 µg	10 µg	2 mg	15 µg	1 mg	15 µg

It is preferred that the combination progestin/estrogen contraceptive be administered in unit dosage form i.e., tablet or pill, with each unit providing the entire daily dosage. It is preferred that the progestin and estrogen are admixed together in the

- 13 -

same dosage unit. Such dosage units can be prepared by conventional methodology that is well known to one skilled in the art. In each dosage unit, the contraceptively active progestin and estrogen are combined with excipients, vehicles, pharmaceutically acceptable carriers, and colorants. For example, the following illustrates an acceptable composition of a contraceptive progestin/estrogen combination of this invention.

EXAMPLE 1

Trimegestone, 125 µg
Ethinyl estradiol, 15 µg
Microcrystalline Cellulose
Lactose, NF, Spray Dried
Polacrillin Potassium, NF
Magnesium Stearate
Opadry Pink
Polyethylene Glycol, 1500, Flakes
Water, Purified, USP
Wax E (Pharma)

This invention also provides a contraceptive kit adapted for daily oral administration which comprises, 3-8 first phase dosage units each containing fixed dosage of a combination of a progestin at a daily dosage of 40-500 µg trimegestone, 250 µg - 4 mg dienogest, or 250 µg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinyl estradiol; 4-15 second phase dosage units each containing fixed dosage of a combination of a progestin at a daily dosage of 40-500 µg trimegestone, 250 µg - 4 mg dienogest, or 250 µg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinyl estradiol, and 4-15 third phase dosage units each containing fixed dosage of a combination of a progestin at a daily dosage of 40-500 µg trimegestone, 250 µg - 4 mg dienogest, or 250 µg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinyl estradiol, such that the total number of combination progestin/estrogen dosage units is 23-25. In another embodiment, the contraceptive kit contains 28 daily dosage units with 4 being a non-contraceptive placebo, that may contain an iron supplement, such as 75 mg ferrous fumarate. The daily dosage arrangements are preferably arranged in a blister pack or in a dial pack type tablet dispenser. Specific referred progestins and estrogens and the specifically preferred dosages of each combination dosage unit are described above.

- 14 -

WHAT IS CLAIMED IS:

1. A method of contraception which comprises administering to a female of child bearing age for 23-25 consecutive days,
 - 5 a first phase combination of a progestin at a daily dosage selected from the group consisting of 440-500 µg trimegestone, 250 µg - 4 mg dienogest, and 250 µg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen
10 combination is administered in each of the 3-8 days,
 - a second phase combination of a progestin at a daily dosage selected from the group consisting of 40-500 µg trimegestone, 250 µg - 4 mg dienogest, and 250 µg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinyl estradiol, for 4-15 days beginning on the day
15 immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days, and
 - a third phase combination of a progestin at a daily dosage selected from the group consisting of 40-500 µg trimegestone, 250 µg - 4 mg dienogest, and 250 µg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 µg ethinyl estradiol, for 4-15 days beginning on the day
20 immediately following the last day of administration of the second phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days
- 25 provided that the daily dosage of the combination administered in the first phase is not the same as the daily dosage of the combination administered in the second phase and that the daily dosage of the combination administered in the second phase is not the same as the daily dosage of the combination administered in the third phase.
30
2. The method according to claim 1, wherein the estrogen is selected from the group consisting of ethinyl estradiol; 17β-estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol.
- 35 3. The method according to claim 2, wherein the estrogen is ethinyl estradiol.

- 15 -

4. The method according to claim 3, wherein
the progestin of the first phase combination is administered at a daily dosage selected
from the group consisting of 40-75 μg trimegestone, 500-750 μg dienogest,
and 500 μg - 2 mg drospirenone,
- 5 the progestin of the second phase combination is administered at a daily dosage selected
from the group consisting of 50-125 μg trimegestone, 750 μg - 1 mg
dienogest, and 1-3 mg drospirenone, and
the progestin of the third phase combination is administered at a daily dosage selected
from the group consisting of 75-250 μg trimegestone, 1-2 mg dienogest, and
10 2-4 mg drospirenone.
5. The method according to claim 4, wherein the total days of administration of the
first phase combination plus the second phase combination plus the third phase
15 combination is 24.
6. The method according to claim 5, wherein the first phase combination is
administered for 7 days, the second phase combination is administered for 7 days, and
the third phase combination is administered for 10 days.
- 20 7. The method according to claim 5, wherein the first phase combination is
administered for 5 days, the second phase combination is administered for 5 days, and
the third phase combination is administered for 14 days.
8. The method according to claim 5, wherein the daily dosage of trimegestone
25 administered in the first phase combination is 50 μg , the daily dosage of trimegestone
administered in the second phase combination is 75 μg , the daily dosage of
trimegestone administered in the third phase combination is 125 μg , the daily dosage
of ethinyl estradiol administered in the first phase combination is 10 μg , the daily
dosage of ethinyl estradiol administered in the second phase combination is 15 μg , and
30 the daily dosage of ethinyl estradiol administered in the third phase combination is
20 μg .
9. The method according to claim 5, wherein the daily dosage of dienogest
administered in the first phase combination is 500 μg , the daily dosage of dienogest
35 administered in the second phase combination is 750 μg , the daily dosage of dienogest
administered in the third phase combination is 1 mg, the daily dosage of ethinyl
estradiol administered in the first phase combination is 10 μg , the daily dosage of

- 16 -

ethinyl estradiol administered in the second phase combination is 15 μ g, and the daily dosage of ethinyl estradiol administered in the third phase combination is 20 μ g.

10. The method according to claim 5, wherein the daily dosage of drospirenone administered in the first phase combination is 1 mg, the daily dosage of drospirenone administered in the second phase combination is 2 mg, the daily dosage of drospirenone administered in the third phase combination is 3 mg, the daily dosage of ethinyl estradiol administered in the first phase combination is 10 μ g, the daily dosage of ethinyl estradiol administered in the second phase combination is 15 μ g, and the daily dosage of ethinyl estradiol administered in the third phase combination is 20 μ g.

11. The method according to claim 3, wherein the progestin of the first phase combination is administered at a daily dosage selected from the group consisting of 40-75 μ g trimegestone, 500-750 μ g dienogest, and 500 μ g - 2 mg drospirenone, the progestin of the second phase combination is administered at a daily dosage selected from the group consisting of 50-125 μ g trimegestone, 750 μ g - 1 mg dienogest, and 1-3 mg drospirenone, and the progestin of the third phase combination is administered at a daily dosage selected from the group consisting of 75-250 μ g trimegestone, 1-2 mg dienogest, and 2-4 mg drospirenone.

12. The method according to claim 11, wherein the total days of administration of the first phase combination plus the second phase combination plus the third phase combination is 24.

13. The method according to Claim 12, wherein the first phase combination is administered for 7 days, the second phase combination is administered for 10 days, and the third phase combination is administered for 7 days.

14. The method according to Claim 12, wherein the first phase combination is administered for 6 days, the second phase combination is administered for 12 days, and the third phase combination is administered for 6 days.

15. The method according to claim 12, wherein the daily dosage of trimegestone administered in the first phase combination is 50 μ g, the daily dosage of trimegestone administered in the second phase combination is 125 μ g, the daily dosage of

- 17 -

trimegestone administered in the third phase combination is 75 μ g, the daily dosage of ethinyl estradiol administered in the first phase combination is 10 μ g, the daily dosage of ethinyl estradiol administered in the second phase combination is 20 μ g, and the daily dosage of ethinyl estradiol administered in the third phase combination is 15 μ g.

5

16. The method according to claim 12, wherein the daily dosage of dienogest administered in the first phase combination is 500 μ g, the daily dosage of dienogest administered in the second phase combination is 1 mg, the daily dosage of dienogest administered in the third phase combination is 750 μ g, the daily dosage of ethinyl estradiol administered in the first phase combination is 10 μ g, the daily dosage of ethinyl estradiol administered in the second phase combination is 20 μ g, and the daily dosage of ethinyl estradiol administered in the third phase combination is 15 μ g.

10

17. The method according to claim 12, wherein the daily dosage of drospirenone administered in the first phase combination is 500 μ g, the daily dosage of drospirenone administered in the second phase combination is 2 mg, the daily dosage of drospirenone administered in the third phase combination is 1 mg, the daily dosage of ethinyl estradiol administered in the first phase combination is 10 μ g, the daily dosage of ethinyl estradiol administered in the second phase combination is 20 μ g, and the daily dosage of ethinyl estradiol administered in the third phase combination is 15 μ g.

15

20

18. The method according to claim 1, which further comprises administering a non-contraceptive placebo for 3-5 consecutive days beginning on the day immediately following the last day of administration of the second phase combination, such that the total days of administration of the first phase combination plus the second phase combination plus the third phase combination plus the non-contraceptive placebo equals 28 days.

25

19. The method according to claim 22 in which the non-contraceptive placebo contains an iron supplement.

30

20. A three phase contraceptive kit adapted for daily oral administration which comprises;

35

3-8 first phase dosage units each containing a combination of a progestin at a daily dosage selected from the group consisting of 40-500 μ g trimegestone, 250 μ g - 4 mg dienogest, and 250 μ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol, provided

- 18 -

that each of the dosage units contains the same dosage of progestin and estrogen;

5 4-15 second phase dosage units each containing a combination of a progestin at a daily dosage selected from the group consisting of 40-500 μ g trimegestone, 250 μ g - 4 mg dienogest, and 250 μ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol, provided that each of the dosage units contains the same dosage of progestin and estrogen, and

10 4-15 third phase dosage units each containing a combination of a progestin at a daily dosage selected from the group consisting of 40-500 μ g trimegestone, 250 μ g - 4 mg dienogest, and 250 μ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol, provided that each of the dosage units contains the same dosage of progestin and estrogen,

15 and provided that the daily dosage of the first phase dosage units are not the same as the daily dosage of the second phase dosage units, and that the daily dosage of the second phase dosage units are not the same as the daily dosage of the third phase dosage units,

20 such that the total number of dosage units in the kit equals 23-25.

21. The contraceptive kit according to claim 20 wherein the estrogen is the same for all three phases and is selected from the group consisting of ethinyl estradiol; 17 β -estradiol; conjugated estrogens, USP; estrone or a salt thereof; and mestranol.

25 22. The contraceptive kit according to claim 21, wherein the total number of dosage units equals 24.

30 23. A contraceptive kit adapted for daily oral administration which comprises;
3-8 first phase dosage units each containing a combination of a progestin at a daily dosage selected from the group consisting of 40-500 μ g trimegestone, 250 μ g - 4 mg dienogest, and 250 μ g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μ g ethinyl estradiol, provided that each of the dosage units contains the same dosage of progestin and estrogen;

35 4-15 second phase dosage units each containing a combination of a progestin at a daily dosage selected from the group consisting of 40-500 μ g trimegestone, 250 μ g - 4 mg dienogest, and 250 μ g - 4 mg drospirenone, and an estrogen at a daily

- 19 -

dosage equivalent in estrogenic activity to 10-20 μg ethinyl estradiol, provided that each of the dosage units contains the same dosage of progestin and estrogen,

- 5 4-15 third phase dosage units each containing a combination of a progestin at a daily dosage selected from the group consisting of 40-500 μg trimegestone, 250 μg - 4 mg dienogest, and 250 μg - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 μg ethinyl estradiol, provided that each of the dosage units contains the same dosage of progestin and estrogen, and
- 10 3-5 dosage units each containing a non-contraceptive placebo, provided that the daily dosage of the first phase dosage units are not the same as the daily dosage of the second phase dosage units, and that the daily dosage of the second phase dosage units are not the same as the daily dosage of the third phase dosage units,
- 15 such that the total number of dosage units in the kit equals 28.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 97/12786

A. CLASSIFICATION OF SUBJECT MATTER

A 61 K 31/57, A 61 K 31/565

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0491415 A1 (AKZO, N.V.) 24 June 1992 (24.06.92), abstract, claims 1,2,7,8, page 3, lines 9-30, page 4, lines 6-39 (cited in the application). --	1-7, 11-14, 18-23
A	US 4616006 A (PASQUALE, S.A.) 07 October 1986 (07.10.86), abstract, claims 1-3,8-10. --	1-7, 11-14, 18,20- 23
A	WO 95/26730 A1 (SCHERING AKTIENGESELLSCHAFT) 12 October 1995 (12.10.95), abstract, claims 1-6 (cited in the application). --	1-7, 10-14, 17,20- 23

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search
12 November 1997

Date of mailing of the international search report

16.12.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

MAZZUCCO e.h.

INTERNATIONAL SEARCH REPORT

-2-

International Application No

PCT/US 97/12786

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0696454 A2 (JENAPHARM GMBH) 14 February 1996 (14.02.96), abstract, claims 1,2,5, column 1, lines 30-57, examples 1-3,7-12 (cited in the application). --	1-7,9, 11-14, 16,20- 23
A	WO 95/17194 A1 (SCHERING AKTIENGESELLSCHAFT) 29 June 1995 (29.06.95), abstract, claims 1-3,9,10, 13-15 (cited in the application). --	1-7, 10-14, 17,18, 20-23
A	WO 95/07081 A1 (SATURNUS AG) 16 March 1995 (16.03.95), abstract, claims 1-7. --	1-7, 10-14, 17,20- 23
A	DE 4313926 A1 (JENAPHARM GMBH) 03 November 1994 (03.11.94), abstract, claims 1-6 (cited in the application). --	1-7,9, 11-14, 16,20- 23
A	EP 0559240 A2 (JENCAP RESEARCH LIMITED) 08 September 1993 (08.09.93), claims 1,14,20,31,35, column 13, lines 26-42. --	1-7, 11-14, 20-23
A	EP 0491438 A (AKZO, N.V.) 24 June 1992 (24.06.92), abstract, claims 1,2,5-7, page 3, line 27 - page 4, line 4. --	1-7, 11-14, 18-23
A	US 3957982 A (LACHNIT-FIXSON, K. et al.) 18 May 1976 (18.05.76), abstract, claims 1-6,12, column 2, line 58 - column 3, line 55 (cited in the application). --	1-7, 11-14, 18,20- 23
A	US 4628051 A (PASQUALE, S.A.) 09 December 1986 (09.12.86), abstract, claims 1-5,13-16, examples 1-8. -----	1-7, 11-14, 18,20- 23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 12786

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-19
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANHANG

zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

ANNEX

to the International Search
Report to the International Patent
Application No.

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/US 97/12786 SAE 167799

In diesem Anhang sind die Mitglieder
der Patentfamilien der im obenge-
nannten internationalen Recherchenbericht
angeführten Patentdokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visée ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A1	491415	24-06-92	AT E 136218 AU A1 89647791 AU B2 6453822 CA AA 2057528 CN A 1062290 DE C0 69118493 DE T2 69118493 EP B1 491415 ES T3 2087964 FI A0 9158553 FI A 9158553 FI B 9908833 IE B 712003 JF A2 4290828 NO A0 9149000 NO A 9149000 NO B 179234 NO C 179234 NZ A 240944 PT A 99782 US A 5262408 ZA A 9109731	15-04-96 18-06-92 13-01-94 14-06-92 01-07-92 09-03-96 22-08-96 03-04-96 01-08-96 12-12-91 14-06-92 30-06-97 12-02-97 15-10-92 12-12-91 15-06-92 28-05-96 04-09-96 26-05-94 31-12-92 16-11-93 30-09-92
US A	4616006	07-10-86	CA A1 1226221 US A 4530839 US A 4544554 US A 4628051	01-09-87 23-07-85 01-10-85 09-12-86
WO A1	9526730	12-10-95	AU A1 20735795 CZ A3 9602879 DE A1 4411585 EP A1 750501 FI A0 963831 FI A 963831 HU A0 9602657 HU A2 75521 NO A0 964089 NO A 964089 PL A1 316569 SK A3 1243796	23-10-95 12-02-97 05-10-95 02-01-97 25-09-96 29-11-96 28-11-96 28-05-97 27-09-96 07-11-96 20-01-97 07-05-97
EP A2	696454	14-02-96	DE C1 4429374 EP A3 696454 JF A2 8169833 US A 5633242	01-02-96 17-07-96 02-07-96 27-05-97
WO A1	9517194	29-06-95	CA AA 2179728 CN A 1142185 CZ A3 9601861 DE A1 4344462 DE C2 4344462 EP A1 735883 HU A0 9601750 HU A2 74877 JF T2 9506888 NO A0 962676 NO A 962676 PL A1 315168 SK A3 831796 US A 5583129	29-06-95 05-02-97 11-12-96 29-06-95 01-02-96 09-10-96 28-08-96 28-02-97 08-07-97 24-06-96 22-08-96 14-10-96 05-02-97 10-12-96
WO A1	9507081	16-03-95	AU A1 76952794 CA AA 2171460 CN A 1133011 EP A1 717626 FI A0 961098 FI A 961098 HU A0 9600592 HU A2 74452 JF T2 9502194 NL A 9301562	27-03-95 16-03-95 09-10-96 26-06-96 08-03-96 03-04-96 28-05-96 30-12-96 04-03-97 03-04-95

1/2

